American Association for Cancer Research
10780432ccr162191-sup-171066_3_unknown_upload_4004366_sp1ss1.pptx (4.78 MB)

Supplementary Figures from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

Download (4.78 MB)
posted on 2023-03-31, 20:01 authored by Xiaowei Xu, Carmine De Angelis, Kathleen A. Burke, Agostina Nardone, Huizhong Hu, Lanfang Qin, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Laura M. Heiser, Nicholas Wang, Charlotte K.Y. Ng, Edward S. Chen, Alexander Renwick, Tao Wang, Sarmistha Nanda, Martin Shea, Tamika Mitchell, Mahitha Rajendran, Ian Waters, Daniel J. Zabransky, Kenneth L. Scott, Carolina Gutierrez, Chandandeep Nagi, Felipe C. Geyer, Gary C. Chamness, Ben H. Park, Chad A. Shaw, Susan G. Hilsenbeck, Mothaffar F. Rimawi, Joe W. Gray, Britta Weigelt, Jorge S. Reis-Filho, C. Kent Osborne, Rachel Schiff

Supplementary Figures S1-S8


NCI Specialized Programs of Research Excellence

Dan L. Duncan Comprehensive Cancer Center

National Cancer Institute

Breast Cancer Research Foundation

Stand Up To Cancer Dream Team Translational Research Grant


Breast Cancer Research Foundation and the Avon Foundation

NIH/National Cancer Institute



Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of alternative survival pathways or reactivation of the HER signaling network. Here we employed BT474 parental and treatment-resistant cell line models to investigate a mechanism by which HER2+ breast cancer can reactivate the HER network under potent HER2-targeted therapies.Experimental Design: Resistant derivatives to lapatinib (L), trastuzumab (T), or the combination (LR/TR/LTR) were developed independently from two independent estrogen receptor ER+/HER2+ BT474 cell lines (AZ/ATCC). Two derivatives resistant to the lapatinib-containing regimens (BT474/AZ-LR and BT474/ATCC-LTR lines) that showed HER2 reactivation at the time of resistance were subjected to massive parallel sequencing and compared with parental lines. Ectopic expression and mutant-specific siRNA interference were applied to analyze the mutation functionally. In vitro and in vivo experiments were performed to test alternative therapies for mutant HER2 inhibition.Results: Genomic analyses revealed that the HER2L755S mutation was the only common somatic mutation gained in the BT474/AZ-LR and BT474/ATCC-LTR lines. Ectopic expression of HER2L755S induced acquired lapatinib resistance in the BT474/AZ, SK-BR-3, and AU565 parental cell lines. HER2L755S-specific siRNA knockdown reversed the resistance in BT474/AZ-LR and BT474/ATCC-LTR lines. The HER1/2–irreversible inhibitors afatinib and neratinib substantially inhibited both resistant cell growth and the HER2 and downstream AKT/MAPK signaling driven by HER2L755S in vitro and in vivo.Conclusions: HER2 reactivation through acquisition of the HER2L755S mutation was identified as a mechanism of acquired resistance to lapatinib-containing HER2-targeted therapy in preclinical HER2-amplified breast cancer models, which can be overcome by irreversible HER1/2 inhibitors. Clin Cancer Res; 23(17); 5123–34. ©2017 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager